Bioxcel Therapeutics, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersNew Haven, CT
US patents17
SAM.gov UEIKRNFT2F99W76
CAGE code8TZQ4
Incorporated inDE
LEI549300Y25FYZ0E8LW260
- IGALMI
- AI-based Drug Re-innovation
Named on the company’s own website, read JUL 29, 2026
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
17 US patents granted 2020–2025, 17 of them in the five years to SEP 2025.
Pharmaceuticals 17
- Non-sedating dexmedetomidine treatment regimensUS 12,364,683 · granted JUL 22, 2025
- Non-sedating dexmedetomidine treatment regimensUS 12,138,247 · granted NOV 12, 2024
- Non-sedating dexmedetomidine treatment regimensUS 12,109,196 · granted OCT 8, 2024
- Non-sedating dexmedetomidine treatment regimensUS 12,090,140 · granted SEP 17, 2024
- Non-sedating dexmedetomidine treatment regimensUS 11,998,529 · granted JUN 4, 2024
Newest 5 shown · Granted to BioXcel Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Bioxcel Therapeutics, INC. | New Haven | CT | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.